You have your summary statement. You have read it twice — the emotional reading and the strategic one. You have triangulated across the three critiques. You have identified where the reviewers converge. You may have emailed your program officer and had the conversation.
And now you are sitting with a question that the entire grantsmanship ecosystem treats as already answered.
Everyone assumes you will resubmit. The mentors. The department chairs. The collaborators who check in and ask how the revision is going. The grantsmanship workshops that pick up at “how to write the Introduction page” as if the only question is how, never whether. The culture of academic science treats resubmission as the default, and anything else — starting over, changing direction, stepping back, letting go — as a deviation that requires justification.
I want to challenge that assumption. Because the decision of whether to resubmit is the most consequential strategic judgment in your funding career. And it is the one you are least likely to receive honest guidance on, because everyone around you has an interest in the answer being yes.
Your mentor wants you to stay productive. Your department wants the indirect costs. Your collaborators have committed time. Your own identity as a scientist is wrapped up in this idea, this question, this project that you have been building toward. The gravitational pull toward resubmission is enormous — and it is not always scientific.
The question I want you to ask before you open a single document is this: What is the strongest strategic move for this science right now?
Sometimes the answer is resubmit. Sometimes it is something else entirely. And the ability to tell the difference is one of the hardest skills in grantsmanship, because it requires separating what you want from what the evidence supports.
Resubmit
Resubmission is the right path when three things are true simultaneously.
First, the critiques point to addressable issues. The reviewers identified concerns that you can substantively resolve within the scope of a revision — strengthened methods, additional preliminary data you already have, a clearer articulation of significance, a team change that fills an expertise gap. The concerns are real, and you can see a clear path to addressing them.
Second, the foundation holds. The reviewers may have raised specific concerns, but the core question, the core design, and the core framing were sound enough that the panel recognized their merit. A resubmission built on a strong foundation is a sharpened version of something that was already close. A resubmission built on a foundation the reviewers did not believe in is a patched version of something that needed to be rebuilt.
Third, the mechanism and the institute are right. Your program officer conversation confirmed that this science fits the portfolio. The study section had the expertise to evaluate your methods. The mechanism matches the scope and stage of the work. If any of these elements are misaligned, a resubmission to the same place faces the same structural headwinds the first submission faced — and no amount of revision addresses a structural mismatch.
When all three conditions hold, resubmit. Resubmit with everything this series has taught you — a narrative Introduction page built around the room’s convergent concern, position aims that assert what you believe, a Significance section that speaks to two audiences, an Approach section that carries the operational confidence of someone who has done this work. The revision is not a response to a list of complaints. It is a rethinking that shows the new panel you heard what the first panel actually said.
If you submitted for the June 2026 cycle and you are planning to resubmit for February 5, the timeline is tight. You need your revision strategy settled by mid-November to have a realistic path to a polished submission. That means this decision — whether to resubmit — needs to happen now.
Restart
There is a version of the resubmission decision that nobody talks about because it sounds like quitting. It is the opposite of quitting. It is the recognition that the science deserves a stronger vehicle than the one you built the first time.
Restart is the right path when the critiques reveal a structural problem — something in the framing, the question, or the design that a revision cannot fix within the constraints of an A1. The reviewers may not have used the word “structural.” They may have written it as a series of specific concerns that, when you triangulate across all three critiques, point to the same underlying issue: the conceptual model does not support the aims, the design does not test what the aims claim, the population does not match the question.
When the foundation is the problem, revising the upper floors does not help. And the A1 resubmission — which is your one shot at revision — is too valuable to spend on a structural patch when the application needs a structural rebuild.
A new A0 submission lets you reconceive the project from the ground up. You keep the science — the question, the population, the expertise, the preliminary data. You rebuild the vehicle. New framing. New design if needed. A new Aims page that reflects what you have learned from the critiques and from the time between submissions. And you enter the review process with a fresh start rather than carrying the weight of a prior score.
This is a harder path emotionally. It feels like going backward. It is going forward with a stronger foundation — which is the only direction that leads to funding.
Redirect
Sometimes the science is strong and the application is strong and the problem is where you sent it.
Study section assignment matters. I have described throughout this series how reviewers bring their own disciplinary lenses and interpretive frameworks to your application. A behavioral intervention grant reviewed by a panel with deep behavioral science expertise is read differently than the same grant reviewed by a panel where behavioral science is peripheral. The best advice I ever received from a program officer is this: choose a study section whose primary discipline already values the outcome you are measuring. You should never have to convince your reviewers that the thing you are trying to improve matters. If you are spending space in your Significance section arguing that lung cancer screening saves lives to a panel of cancer prevention scientists, you are in the right room. If you are making that case to a panel that studies something else entirely, your application is doing work the study section assignment should have done for you.
If your critiques suggest that the reviewers did not fully understand your methods, your theoretical framework, or the population context — and your program officer conversation confirms that the expertise match was imperfect — a resubmission to the same study section faces the same interpretive gap.
Redirect means sending the same science — or an evolved version of it — through a different structural path. That might be a different study section, requested through CSR. It might be a different institute, if your PO suggested that the portfolio fit is stronger elsewhere. It might be a different mechanism — an R21 to build the preliminary data that the reviewers said was insufficient, an R34 for the planning phase of a complex intervention, a different R01 funding opportunity announcement that better matches your science.
Redirect requires the program officer conversation. It is the path you cannot evaluate alone, because the structural knowledge — which study sections have the right expertise, which institutes are prioritizing which topics, which mechanisms match your current stage — lives with the people who manage the system. Ask them. That is what they are there for.
Wait
This is the option that requires the most discipline, because the February deadline is real and the pressure to submit is constant.
Wait is the right path when the critiques identified a gap that you cannot close in time. Insufficient preliminary data. A methodological approach that needs piloting. A community partnership that has not matured enough to support the proposed scope. A team member you need but have not yet identified.
Submitting before these gaps are closed, because the deadline exists, is one of the most common strategic errors I see. The application goes in with the same vulnerability it had the first time — and the reviewers find it again, because the vulnerability is real. You have spent your one resubmission on a revision that was not ready.
The deadline comes twice a year. February and June. If February is too soon, June gives you four more months. If June is too soon, the next February gives you twelve. The question is whether the submission you can produce by February 5 is the strongest possible version of this application — or whether four more months of preliminary work, piloting, or team-building would produce a fundamentally different submission.
I have submitted grants before they were ready. I have also waited when the deadline was calling. The grants I waited on were funded at higher rates than the ones I rushed. That is a sample size of one career, and I offer it as experience rather than evidence. But the pattern holds across every investigator I have mentored: the applications that are funded are the ones that were ready, and readiness does not align with the calendar.
Release
This is the option nobody names. I need to name it, because some of you are carrying applications that are no longer the best use of your scientific energy, and the weight of that carrying is costing you more than a nonfunding decision ever did.
Release is the right path when the science has moved. When the question you wrote three years ago is no longer the most urgent version of the question. When the field has advanced past the innovation you proposed. When your own thinking has evolved and the project you are revising no longer reflects where your science is heading.
Release is also the right path when the critiques reveal something you have been reluctant to face: this particular project, in this form, does not have a viable path to funding — and the continued investment of time, energy, and emotional capital is pulling you away from the work that does.
Releasing an application is not the same as abandoning the science. The question still matters. The expertise you built still transfers. The preliminary data still informs your next project. What you release is the specific vehicle — this application, this design, this framing — and what you gain is the freedom to channel that expertise toward a project with a stronger path.
I know this is hard. I know the attachment to a project can feel like attachment to your identity as a scientist. Letting go of an application can feel like letting go of the version of yourself who wrote it. And I know that the culture of academic science rewards persistence in a way that makes release feel like failure.
It is the opposite of failure. It is the scientific judgment to allocate your most limited resource — your time and attention — toward the work with the highest likelihood of impact. That judgment is one of the most important things a senior scientist develops. And it is one of the least taught.
How I made this decision
My CLEAR-Lung R01 — the study that is now funded and in its first year — was submitted three times. I made the resubmission decision twice.
The first time, the decision was clear. The critiques pointed to addressable issues. The foundation was strong. The study section had the right expertise. I rewrote the Introduction page around the room’s convergent concern, strengthened the Approach, and resubmitted.
The second time was harder. The A1 had scored well (6th percentile) but had not been funded — the payline that cycle moved unexpectedly due to forces outside of our control and no longer reached my percentile. I had to decide whether to submit a new A0 with the same science, reconceived. That meant starting the review process over. New reviewers who had never seen the prior submission. No credit for the revisions I had already made. No Introduction page to demonstrate responsiveness.
I chose to restart because the science had evolved. My own understanding of the problem had deepened between submissions in ways that the A1 framework could not contain. The A0 I wrote was a fundamentally different application — same question, same population, same commitment — with a design and a framing that reflected what I had learned. It was funded on the first review of that new submission.
I tell you this to make one point: the decision of whether to resubmit is not a measure of persistence or commitment. It is a scientific and strategic judgment, made with the best information available, about which path gives your science the strongest chance of reaching the people it is meant to serve.
Making the decision
Here is what I would ask you to do this week.
Read your summary statement one more time — the strategic reading, from the second pass. Then answer five questions honestly, in writing, for yourself:
Do the critiques point to issues I can substantively address within a revision? Or do they point to something structural in the foundation?
Is this the right mechanism, the right institute, and the right study section for this science?
Can I produce the strongest possible version of this application by February 5? Or would waiting produce a fundamentally different submission?
Has my own scientific thinking evolved past what this application proposes?
If I were advising a colleague with these exact critiques and this exact score, what would I tell them to do?
The last question is the one that cuts through the noise. Because when it is someone else’s application, you can see the strategic landscape clearly. The attachment is gone. The institutional pressure is absent. The answer is obvious.
Give yourself the clarity you would give a colleague. Your science deserves that honesty.
What is one funding decision — resubmit, restart, redirect, wait, or release — that you made in your career that changed the trajectory of your work?
~Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
More insights at lisacarterbawa.com/insights
Lost In Translation (LIT) grantsmanship curriculum is available as a self-paced online course and as an intensive institutional cohort for cancer centers, training programs, and research-intensive departments. Module 1 is free.
I also run small cohorts timed to the NIH grant submission cycle — five live Monday sessions, full access to the LIT course (14 modules + 13 workbooks), and a post-cohort Translation Feedback Brief: a one-on-one review of your revised Aims page and/or full grant returned in time for your submission.
If you are interested in an upcoming cohort, indicate interest here: https://forms.gle/Eysi8qEjBXNY1w388
Contact lisa@soultosoulleadership.com with any questions or visit lisacarterbawa.com/losttranslation to learn more.
If you want to bring Lost In Translation to your institution, find more information here: https://www.lisacarterbawa.com/institutions
